Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-03-31
2010-10-19
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S159100, C435S029000
Reexamination Certificate
active
07815914
ABSTRACT:
The present invention relates to methods of identifying the susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling. The invention also pertains to methods using reovirus for the treatment of cellular proliferative disorders, and particularly cellular proliferative disorders wherein the proliferating cells exhibit constitutive MAPK phosphorylation, in mammals. In particular, the methods provide for reovirus treatment of mammals to treat proliferative disorders which include breast tumors, a subset of tumors in which mutation of the ras gene is not believed to play a significant role.
REFERENCES:
patent: 5023252 (1991-06-01), Hseih
patent: WO 99/08692 (1999-02-01), None
patent: WO99/08692 (1999-02-01), None
patent: WO 00/50051 (2000-03-01), None
Migliaccio et al., The EMBO Journal vol. 15. p. 1292-1300, 1996.
Archer, S.G., et al. (1995). Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 72(5):1259-1266.
Armstrong, G.D., et al. (1984). Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes. Virology. 138(1):37-48.
Barbacid, M. (1987). ras genes. Annu Rev Biochem, 56:779-827.
Baselga, J., et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2
eu-overexpressing metastatic breast cancer. J Clin Oncol. 14(3):737-744.
Bos, J.L., (1989). ras oncogenes in human cancer: a review. Cancer Res. 49(17):4682-4689.
Carter, P., et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89(10):4285-4289.
Chandron, K., and Nibert, M.L. (1998). Protease cleavage of reovirus capsid protein μ1/μ1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle. J Virol. 72(1):467-475.
Chaubert, P., et al. (1994). K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol. 144(4):767-775.
Clark, E.A., and Brugge, J.S. (1995). Integrins and signal transduction pathways: the road taken. Science. 268(5208):233-239.
Clark, J.W., et al. (1996). Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway. Int J Cancer. 65(2):186-191.
Coffey, M.C. et al. (1998) Reovirus therapy of tumors with activated Ras pathway. Science. 282(5392):1332-1334.
Cuff, C.F., et al. (1998). Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract. Toxicol Sci. 42(2):99-108
Di Domenico, M., et al. (1996). Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res. 56(19):4516-4521.
Duncan, R., et al. (1991), Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein. Virology. 182(2):810-819.
Dvorak, H.F., et al. (1988), Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 133(1):95-109.
Gentsch, J.R., and Pacitti, A.F. (1985). Effect of neuraminidase treatment of cells. J Virol. 56(2):356-364.
Harwerth, I.M., et al. (1992), Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem. 267(21):15160-15167.
Hudziak, R.M., et al. (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 9(3):1165-1172.
Hung, M.C., et al. (1995). HER-2
eu-targeting gene therapy—a review. Gene. 159(1):65-71.
Ikeda, K., et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 5(8):881-887.
Ikeda, K., et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol. 74(10):4765-4775.
Jacobs, C., and Rubsamen, H. (1983). Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 43(4):1696-1702.
Janes, P.W., et al. (1994). Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene. 9(12):3601-3608.
Jardines, L., et al. (1993), neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology. 61(5-6):268-282.
Koenders, P.G., et al. (1991). Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 51(17):4544-4548.
Lee, J.M., and Bernstein, A. (1993). p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA. 90(12):5742-5746.
Lee, P.W., et al. (1981), Characterization of anti-reovirus immunoglobulins secreted by cloned hybridoma cell lines. Virology, 108(1):134-146.
Levitski, A. (1994), Signal-transduction therapy. A novel approach to disease management, Eur J Biochem. 226(1):1-13.
Lowe, S. W., et al. (1994). p53 status and the efficacy of cancer therapy in vivo. Science. 266(5186):807-810.
Mah, D.C., et al. (1990). The N-terminal quarter of reovirus cell attachment protein σ1 possesses intrinsic virion-anchoring function. Virology, 179(1):95-103.
Migliaccio, A., et al. (1996). Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15(6):1292-1300.
Migliaccio, A., et al. (1998). Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17(7):2008-2018.
Mills, N.E., et al. (1995). Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 55(7):1444-1447.
Nagy, J.A., et al. (1989). Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta. 948(3):305-326.
Nguyen, D.H., et al. (1999). Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner, J Cell Biol. 146(1):149-164.
Norman, K.L., and Lee, P.W. (2000). Reovirus as a novel oncolytic agent. J Clin Invest. 105(8):1035-1038.
Paasinen-Sohns, A., and Hölttä, E. (1997). Cells transformed by ODC,c-Ha-rasand v-srcexhibit MAP kinase/Erk-independent constitutive phosphorylation of Sos, Raf andc-Jun activation domain, and reduced PDGF receptor expression. Oncogene. 15(16):1953-1966.
Paul, R.W., et al. (1989). The α-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus. Virology. 172(1):382-385.
Píetras, R.J., et al. (1994). Antibody to HER-2
eu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 9(7):1829-1838.
Raybaud-Diogene, H., et al. (1997). Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol. 15(3):1030-1038.
Robinson, M.J., and Cobb, M.H. (1997). Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 9(2):180-186.
Rosen, L. (1960). Serologic grouping of reoviruses by hemagglutination-hibition. Am J Hyg. 71:242-249.
Shackney, S.E., et al. (1998). Intracellular coexpression of epidermal growth factor receptor, Her-2
eu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients, Clin Cancer Res. 4(4):913-928.
Slamon, D.J., et al. (1989). Studies of the HER-2
eu proto-oncogene in human breast and ovarian cancer. Science. 24(4905):707-712.
Smith, R.E., et al. (1969). Polypeptide components of virions, top component and cores of reovirus type 3. Virology, 39(4):791-810.
Spandidos, D.A. (1987). Oncogene activation in malignant transformation: a study of H-ras in human breast cancer
Fish & Richardson P.C.
Helms Larry R.
Oncolytics Biotech Inc.
Yao Lei
LandOfFree
Methods for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4233809